Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 36322Q206 since 12/18/2024, largest first.
| Filer | % of Class | Filed | ||
|---|---|---|---|---|
|
Fairmount Funds Management LLC
13D/A
|
20.0% |
2/11/2026
Event 2/9/2026
|
||
| Fairmount Funds Management LLC | 20.0% | |||
| Fairmount Healthcare Fund II L.P. | 13.3% | |||
| Fairmount Healthcare Co-Invest V L.P. | 6.7% | |||
| Peter Evan Harwin | 20.0% | |||
| Tomas Kiselak | 20.0% | |||
|
FMR LLC
13G
|
15.0% |
12/5/2025
Event 11/28/2025
|
||
| FMR LLC | 15.0% | |||
| Abigail P. Johnson | 15.0% | |||
|
Avoro Capital Advisors LLC
13G
|
6.3% |
5/15/2026
Event 3/31/2026
|
||
| Avoro Capital Advisors LLC | 6.3% | |||
| Behzad Aghazadeh | 6.3% | |||
|
Venrock Healthcare Capital Partners III, L.P.
13G
|
6.0% |
2/17/2026
Event 2/9/2026
|
||
| Venrock Healthcare Capital Partners III, L.P. | 6.0% | |||
| VHCP Co-Investment Holdings III, LLC | 6.0% | |||
| Venrock Healthcare Capital Partners EG, L.P. | 6.0% | |||
| VHCP Management III, LLC | 6.0% | |||
| VHCP Management EG, LLC | 6.0% | |||
| Nimish Shah | 6.0% | |||
| Bong Y. Koh | 6.0% | |||
| BlackRock, Inc. 13G | 5.1% |
7/28/2026
Event 6/30/2026
|
||
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (4) | ||||
| Paragon Therapeutics, Inc. 13G/A | 3.4% |
4/23/2026
Event 2/9/2026
|
||
| Paramora Holding LLC 13G/A | 3.4% |
4/23/2026
Event 2/9/2026
|
||
|
Point72 Asset Management, L.P.
13G/A
|
2.0% |
5/15/2026
Event 3/31/2026
|
||
| Point72 Asset Management, L.P. | 2.0% | |||
| Point72 Capital Advisors, Inc. | 2.0% | |||
| Steven A. Cohen | 2.0% | |||
|
Jain Global LLC
13G/A
|
0% |
5/15/2026
Event 3/31/2026
|
||
| Jain Global LLC | 0% | |||
| Jain Holdings LLC | 0% | |||
| Robert Jain | 0% | |||
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 1 | 140 | $2.98 k |
| 2026 Q2 | 104 | 65.9 M | $1.72 B |
| 2026 Q1 | 66 | 56.1 M | $1.45 B |
| 2025 Q4 | 18 | 1.11 M | $62.7 M |
| 2025 Q3 | 12 | 170 k | $633 k |
| 2025 Q2 | 10 | 133 k | $451 k |
| 2025 Q1 | 12 | 143 k | $442 k |
| 2024 Q4 | 11 | 142 k | $661 k |
| 2024 Q3 | 11 | 129 k | $1.56 M |